Fig. 4.

[¹⁸F]fluorodeoxyglucose (¹⁸F-FDG) PET imaging analysis of chemogenetic heart failure after treatments with sacubitril/valsartan or valsartan. A: representative ¹⁸F-FDG PET images of water-treated control, d-amino acid oxidase (DAAO)-expressing rats treated with water, or DAAO-expressing rats following treatments with either sacubitril/valsartan (Sac/val) or valsartan (Val). B: quantitative data of glucose uptake rate (left) and glucose utilization (right) of control (n = 3), DAAO-expressing rats (n = 4), or DAAO-infected rats following treatments with sacubitril/valsartan (n = 3) or valsartan (n = 3). **P < 0.01 obtained by Kruskal-Wallis test followed by Dunn’s multiple-comparison test. Data are represented as means ± SE. Here, cc, cubic centimeters; SUV, standardized uptake value.